Oral human papillomavirus (HPV) prevalence in youth and cervical HPV prevalence in women attending a youth clinic in Sweden, a follow up-study 2013-2014 after gradual introduction of public HPV vaccination

Infectious Diseases

Volumn 47, Issue 1, 2015, Pages 57-61

  Grün, Nathalie ^a   Ährlund Richter, Andreas ^a   Franzén, Joar ^a   Mirzaie, Leila ^a   Marions, Lena ^a   Ramqvist, Torbjörn ^a   Dalianis, Tina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cervical HPV infection; HPV; HPV in youth; HPV vaccination; Oral HPV infection

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 70; HUMAN PAPILLOMAVIRUS TYPE 73; JUVENILE; MALE; MOUTH; NONHUMAN; PREVALENCE; SWEDEN; UTERINE CERVIX; VACCINATION; WART VIRUS; MASS IMMUNIZATION; MOUTH DISEASES; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL DISEASES; VIROLOGY; YOUNG ADULT;

ADOLESCENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS VACCINATION; MOUTH DISEASES; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SWEDEN; UTERINE CERVICAL DISEASES; YOUNG ADULT;

EID: 84925841944     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365548.2014.964764     Document Type: Article

References (17)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-17.
2. Ramqvist T, Dalianis T. O ropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis 2010; 16: 1671-77.
3. Ramqvist T, Du J, Lunden M,ährlund-Richter S, Ferreira J, Marions L, et al. Pre-vaccination prevalence of human papillomavirus types in the genital tract of 15-23-year-old women attending a youth health clinic in Stockholm, Sweden. Scand J Infect Dis 2011; 43: 115-21.
4. Du J, Nordfors C,ährlund-Richter A, Sobkowiak M, Romanitan M, Nasman A, et al. Prevalence of oral human papillomavirus infection among youth, Sweden. Emerg Infect Dis 2012; 18: 1468-71.
5. Leval A, Herweijer E, Arnheim-Dahlström L, Walum H, Frans E, Sparén P, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012; 206: 860-6.
6. Kreimer AR, Bhatia RK, Messeguer A L, Gonzalez P, Herrero R, Giuliano AR. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 2010; 37: 386-91.
7. Nordfors C, Grün N, Haeggblom L, Tertipis N, Sivars L, Mattebo M, et al. Oral human papillomavirus prevalence in high school students of one municipality in Sweden. Scand J Infect Dis 2013; 45: 878-81.
8. Mattebo M, Grün N, Rosenblad A, Larsson M, Häggström-Nordin E, Dalianis T, et al. Sexual experiences in relation to HPV vaccination status in female high school students in Sweden. Eur J Contracept Reprod Health Care 2014; 19: 86-92.
9. Munoz N, Bosch F X, d e Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classifi cation of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
10. IARC. Human papillomaviruses. In: IARC Monographs on the Evaluation of carcinogenic risk to humans, Volume 100B. A review of human carcinogens. Biological agents. WHO; 2011 pp 261-301.
11. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. CVT Vaccine Group. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013; 8: e68329.
12. Antonsson A, Cornford M, Perry S, Davis M, Dunne MP, Whiteman DC. Prevalence and risk factors for oral HPV infection in young Australians. PLoS One 2014; 9: e91761.
13. Cook RL, Thomson EL, Kelso NE, Friary J, Hosford J, Barkley P, et al. Sexual behaviours and other risk factors for oral human papillomavirus infections in young women. Sex Transm Dis 2014; 41; 486-92.
14. Baudu A, Prétet J L, Riethmuller D, Chotard M, Mougin C, Mercier M. Prevalence and risk factors of human papillomavirus infection types 16/18/45 in a cohort of French females aged 15-23 years. J Epidemiol Glob Health 2014; 4: 35-43.
15. Tabrizi SN, Brotherton J M, Kaldor J M, Skinner SR, Cummins E, Liu B, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206: 1645-51.
16. Markowitz L E, Hariri S, Lin C, Dunne E F, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208: 385-93.
17. DeleréY, Remschmidt C, Leuschner J, Schuster M, Fesenfeld M, Schneider A, et al. Human Papillomavirus prevalence and probable fi rst effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis 2014; 14: 87.